Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will make an assessment of the cost-effectiveness of a Type 1 Diabetes screening programme.

In the United Kingdom, new screening programmes and modifications to existing screening programmes are recommended by the UK National Screening Committee (UK NSC), an independent scientific advisory committee.

The UK NSC received a submission via its 2024 open call process to consider screening for autoimmune type 1 diabetes through blood testing. Once the National Institute for Health and Care Excellence has published its recommendation on the drug teplizumab, the UK NSC will look again at this open call submission and consider whether a fresh review of the evidence for type 1 diabetes screening should be undertaken.